Prior studies found that patients who have CLL cells with high levels of ROR1 had a shorter median time from diagnosis to initial therapy and shorter median overall survival than patients who had CLL cells with low-to-negligible ROR1 [11]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.